Literature DB >> 1833421

Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo.

M Levi1, C E Hack, J P de Boer, D P Brandjes, H R Büller, J W ten Cate.   

Abstract

In this study the contribution of activation of the contact system to activation of the fibrinolytic system in vivo was investigated in healthy volunteers and in factor XII deficient patients. The plasminogen activating activity in plasma from healthy volunteers after infusion of desamino D-arginine vasopressin (DDAVP) was only partially blocked (for 77%) with specific antibodies to tissue-type plasminogen activator and urokinase type plasminogen activator. The residual activity could be quenched by a monoclonal antibody that inhibits factor XII activity and was not present in patients with a factor XII deficiency. The formation of plasmin upon the DDAVP stimulus as reflected by circulating plasmin-alpha 2-antiplasmin complexes was lower in factor XII deficient patients than in healthy volunteers. Activation of the contact system occurred after DDAVP infusion in healthy volunteers and was absent in factor XII deficient patients. These results indicate that DDAVP induces a plasminogen activating activity that is partially dependent on activation of the contact system and that contributes to the overall fibrinolytic activity as indicated by the formation of plasmin-alpha 2-antiplasmin complexes. This fibrinolytic activity is impaired in factor XII deficient patients which may explain the occurrence of thromboembolic complications in these patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1833421      PMCID: PMC295573          DOI: 10.1172/JCI115416

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

Review 1.  Role of the contact system in fibrinolysis.

Authors:  C Kluft; G Dooijewaard; J J Emeis
Journal:  Semin Thromb Hemost       Date:  1987-01       Impact factor: 4.180

2.  Quantitation of urokinase antigen in plasma and culture media by use of an ELISA.

Authors:  D J Binnema; J J van Iersel; G Dooijewaard
Journal:  Thromb Res       Date:  1986-09-01       Impact factor: 3.944

3.  The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragments.

Authors:  G H Goldsmith; H Saito; O S Ratnoff
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

4.  The contact-system dependent plasminogen activator from human plasma: identification and characterization.

Authors:  D J Binnema; G Dooijewaard; J J van Iersel; P N Turion; C Kluft
Journal:  Thromb Haemost       Date:  1990-11-30       Impact factor: 5.249

5.  Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis.

Authors:  J H Nuijens; C C Huijbregts; A J Eerenberg-Belmer; J J Abbink; R J Strack van Schijndel; R J Felt-Bersma; L G Thijs; C E Hack
Journal:  Blood       Date:  1988-12       Impact factor: 22.113

6.  DDAVP induces systemic release of urokinase-type plasminogen activator.

Authors:  M Levi; J W ten Cate; G Dooijewaard; A Sturk; E J Brommer; G Agnelli
Journal:  Thromb Haemost       Date:  1989-09-29       Impact factor: 5.249

7.  Thromboembolism and bleeding tendency in congenital factor XII deficiency--a study on 74 subjects from 14 Swiss families.

Authors:  B Lämmle; W A Wuillemin; I Huber; M Krauskopf; C Zürcher; R Pflugshaupt; M Furlan
Journal:  Thromb Haemost       Date:  1991-02-12       Impact factor: 5.249

8.  Tissue plasminogen activator release in vivo in response to vasoactive agents.

Authors:  D Smith; M Gilbert; W G Owen
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

9.  Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA.

Authors:  P Holvoet; H Cleemput; D Collen
Journal:  Thromb Haemost       Date:  1985-10-30       Impact factor: 5.249

10.  A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

View more
  13 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

2.  Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency.

Authors:  M van Geffen; M Cugno; P Lap; A Loof; M Cicardi; W van Heerde
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

3.  Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus.

Authors:  Maria Laura Bertolaccini; Kirti Mepani; Giovanni Sanna; Graham R V Hughes; Munther A Khamashta
Journal:  Ann Rheum Dis       Date:  2006-10-04       Impact factor: 19.103

4.  Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Georgi Georgiev; Anja Klemmer; Chelsea Brain; Paul Y Kim; Nicola J Mutch
Journal:  Blood       Date:  2016-09-30       Impact factor: 22.113

Review 5.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

6.  Impaired fibrinolysis in the hemolytic-uremic syndrome of childhood.

Authors:  D Menzel; M Levi; G Dooijewaard; M Peters; J W ten Cate
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

Review 7.  Pathophysiology of Hereditary Angioedema.

Authors:  Sonia Caccia; Chiara Suffritti; Marco Cicardi
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2014-12-01       Impact factor: 1.349

8.  Contact pathway of coagulation and inflammation.

Authors:  Yi Wu
Journal:  Thromb J       Date:  2015-05-06

Review 9.  The Story of Angioedema: from Quincke to Bradykinin.

Authors:  Avner Reshef; Mona Kidon; Iris Leibovich
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 10.817

10.  Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees.

Authors:  T van der Poll; M Levi; C E Hack; H ten Cate; S J van Deventer; A J Eerenberg; E R de Groot; J Jansen; H Gallati; H R Büller
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.